413 related articles for article (PubMed ID: 33309661)
1. Ritonavir may inhibit exoribonuclease activity of nsp14 from the SARS-CoV-2 virus and potentiate the activity of chain terminating drugs.
Narayanan N; Nair DT
Int J Biol Macromol; 2021 Jan; 168():272-278. PubMed ID: 33309661
[TBL] [Abstract][Full Text] [Related]
2. New targets for drug design: importance of nsp14/nsp10 complex formation for the 3'-5' exoribonucleolytic activity on SARS-CoV-2.
Saramago M; Bárria C; Costa VG; Souza CS; Viegas SC; Domingues S; Lousa D; Soares CM; Arraiano CM; Matos RG
FEBS J; 2021 Sep; 288(17):5130-5147. PubMed ID: 33705595
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the SARS-CoV-2 ExoN (nsp14ExoN-nsp10) complex: implications for its role in viral genome stability and inhibitor identification.
Baddock HT; Brolih S; Yosaatmadja Y; Ratnaweera M; Bielinski M; Swift LP; Cruz-Migoni A; Fan H; Keown JR; Walker AP; Morris GM; Grimes JM; Fodor E; Schofield CJ; Gileadi O; McHugh PJ
Nucleic Acids Res; 2022 Feb; 50(3):1484-1500. PubMed ID: 35037045
[TBL] [Abstract][Full Text] [Related]
4. Structure and dynamics of SARS-CoV-2 proofreading exoribonuclease ExoN.
Moeller NH; Shi K; Demir Ö; Belica C; Banerjee S; Yin L; Durfee C; Amaro RE; Aihara H
Proc Natl Acad Sci U S A; 2022 Mar; 119(9):. PubMed ID: 35165203
[TBL] [Abstract][Full Text] [Related]
5. Activation of the SARS-CoV-2 NSP14 3'-5' exoribonuclease by NSP10 and response to antiviral inhibitors.
Riccio AA; Sullivan ED; Copeland WC
J Biol Chem; 2022 Jan; 298(1):101518. PubMed ID: 34942146
[TBL] [Abstract][Full Text] [Related]
6. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp14/nsp10 exoribonuclease.
Canal B; McClure AW; Curran JF; Wu M; Ulferts R; Weissmann F; Zeng J; Bertolin AP; Milligan JC; Basu S; Drury LS; Deegan TD; Fujisawa R; Roberts EL; Basier C; Labib K; Beale R; Howell M; Diffley JFX
Biochem J; 2021 Jul; 478(13):2445-2464. PubMed ID: 34198326
[TBL] [Abstract][Full Text] [Related]
7. Label-Free Screening of SARS-CoV-2 NSP14 Exonuclease Activity Using SAMDI Mass Spectrometry.
Scholle MD; Liu C; Deval J; Gurard-Levin ZA
SLAS Discov; 2021 Jul; 26(6):766-774. PubMed ID: 33870746
[TBL] [Abstract][Full Text] [Related]
8. Development of a High-Throughput Screening Assay to Identify Inhibitors of the SARS-CoV-2 Guanine-N7-Methyltransferase Using RapidFire Mass Spectrometry.
Pearson LA; Green CJ; Lin D; Petit AP; Gray DW; Cowling VH; Fordyce EAF
SLAS Discov; 2021 Jul; 26(6):749-756. PubMed ID: 33724070
[TBL] [Abstract][Full Text] [Related]
9. Crystal structure of SARS-CoV-2 nsp10 bound to nsp14-ExoN domain reveals an exoribonuclease with both structural and functional integrity.
Lin S; Chen H; Chen Z; Yang F; Ye F; Zheng Y; Yang J; Lin X; Sun H; Wang L; Wen A; Dong H; Xiao Q; Deng D; Cao Y; Lu G
Nucleic Acids Res; 2021 May; 49(9):5382-5392. PubMed ID: 33956156
[TBL] [Abstract][Full Text] [Related]
10. The Enzymatic Activity of the nsp14 Exoribonuclease Is Critical for Replication of MERS-CoV and SARS-CoV-2.
Ogando NS; Zevenhoven-Dobbe JC; van der Meer Y; Bredenbeek PJ; Posthuma CC; Snijder EJ
J Virol; 2020 Nov; 94(23):. PubMed ID: 32938769
[TBL] [Abstract][Full Text] [Related]
11. A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase.
Zhao J; Guo S; Yi D; Li Q; Ma L; Zhang Y; Wang J; Li X; Guo F; Lin R; Liang C; Liu Z; Cen S
Antiviral Res; 2021 Jun; 190():105078. PubMed ID: 33894278
[TBL] [Abstract][Full Text] [Related]
12. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp14 RNA cap methyltransferase.
Basu S; Mak T; Ulferts R; Wu M; Deegan T; Fujisawa R; Tan KW; Lim CT; Basier C; Canal B; Curran JF; Drury LS; McClure AW; Roberts EL; Weissmann F; Zeisner TU; Beale R; Cowling VH; Howell M; Labib K; Diffley JFX
Biochem J; 2021 Jul; 478(13):2481-2497. PubMed ID: 34198328
[TBL] [Abstract][Full Text] [Related]
13. Coronavirus genomic nsp14-ExoN, structure, role, mechanism, and potential application as a drug target.
Tahir M
J Med Virol; 2021 Jul; 93(7):4258-4264. PubMed ID: 33837972
[TBL] [Abstract][Full Text] [Related]
14. Vitamin B12 may inhibit RNA-dependent-RNA polymerase activity of nsp12 from the SARS-CoV-2 virus.
Narayanan N; Nair DT
IUBMB Life; 2020 Oct; 72(10):2112-2120. PubMed ID: 32812340
[TBL] [Abstract][Full Text] [Related]
15. The coronavirus proofreading exoribonuclease mediates extensive viral recombination.
Gribble J; Stevens LJ; Agostini ML; Anderson-Daniels J; Chappell JD; Lu X; Pruijssers AJ; Routh AL; Denison MR
PLoS Pathog; 2021 Jan; 17(1):e1009226. PubMed ID: 33465137
[TBL] [Abstract][Full Text] [Related]
16. Analogs of the Catechol Derivative Dynasore Inhibit HIV-1 Ribonuclease H, SARS-CoV-2 nsp14 Exoribonuclease, and Virus Replication.
Asthana A; Corona A; Shin WJ; Kwak MJ; Gaughan C; Tramontano E; Jung JU; Schobert R; Jha BK; Silverman RH; Biersack B
Viruses; 2023 Jul; 15(7):. PubMed ID: 37515225
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 nsp14 Exoribonuclease Removes the Natural Antiviral 3'-Deoxy-3',4'-didehydro-cytidine Nucleotide from RNA.
Moeller NH; Passow KT; Harki DA; Aihara H
Viruses; 2022 Aug; 14(8):. PubMed ID: 36016411
[TBL] [Abstract][Full Text] [Related]
18. Structure-Based Virtual Screening for Methyltransferase Inhibitors of SARS-CoV-2 nsp14 and nsp16.
Wu K; Guo Y; Xu T; Huang W; Guo D; Cao L; Lei J
Molecules; 2024 May; 29(10):. PubMed ID: 38792173
[TBL] [Abstract][Full Text] [Related]
19. Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites.
Shannon A; Le NT; Selisko B; Eydoux C; Alvarez K; Guillemot JC; Decroly E; Peersen O; Ferron F; Canard B
Antiviral Res; 2020 Jun; 178():104793. PubMed ID: 32283108
[TBL] [Abstract][Full Text] [Related]
20. Analysis of critical protein-protein interactions of SARS-CoV-2 capping and proofreading molecular machineries towards designing dual target inhibitory peptides.
Arabi-Jeshvaghani F; Javadi-Zarnaghi F; Ganjalikhany MR
Sci Rep; 2023 Jan; 13(1):350. PubMed ID: 36611052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
